Ignite Creation Date:
2025-12-24 @ 10:34 PM
Ignite Modification Date:
2026-02-01 @ 4:30 PM
Study NCT ID:
NCT04882735
Status:
WITHDRAWN
Last Update Posted:
2024-09-19
First Post:
2021-04-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
Sponsor:
Eidos Therapeutics, a BridgeBio company
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | TTR | View |
| None | ATTR-PN | View |
| None | Familial ATTR-PN | View |
| None | Amyloidosis | View |
| None | Amyloid | View |
| None | Transthyretin | View |
| None | Polyneuropathy | View |
| None | TTR-mediated amyloidosis | View |
| None | Amyloidosis, hereditary | View |
| None | Familial Amyloid Polyneuropathies | View |
| None | Amyloidosis, Hereditary, Transthyretin-Related | View |